Johnson & Johnson Violated FDA Order to Halt Sales of Transvaginal Mesh

Ennis & Ennis, PA Explains J&J Continued to Market Gynecare Prolift Despite FDA Order (PRWEB) June 27, 2012 In complete disregard of an order by the U.S. Food and Drug Administration (FDA) to stop marketing the Gynecare Prolift vaginal mesh implant, Johnson and Johnson (J&J) continued to sell the product for nine additional months. According to court records, in a letter dated August 24, 2007, the FDA advised J&J to halt the sales of the Gynecare Prolift until such time the agency determined whether the device was the “substantially equivalent” to other mesh products on th

Contributor